Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

ClinicalTrials.gov ID: NCT02792699

Public ClinicalTrials.gov record NCT02792699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe RA. This study will also assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.

Study identification

NCT ID
NCT02792699
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
311 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 16, 2016
Primary completion
Oct 7, 2018
Completion
Oct 7, 2018
Last update posted
Oct 5, 2020

2016 – 2018

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
27
Facility City State ZIP Site status
Research Site Tuscaloosa Alabama 35406
Research Site Los Angeles California 90095-1670
Research Site Thousand Oaks California 91360
Research Site Upland California 91786
Research Site Aventura Florida 33180
Research Site Edgewater Florida 32132
Research Site Hialeah Florida 33012
Research Site Orlando Florida 32810
Research Site Vero Beach Florida 32960
Research Site Idaho Falls Idaho 83404
Research Site Lexington Kentucky 40504
Research Site Lansing Michigan 48910
Research Site Flowood Mississippi 39232
Research Site Las Vegas Nevada 89128
Research Site Charlotte North Carolina 28210
Research Site Oklahoma City Oklahoma 73112
Research Site Duncansville Pennsylvania 16635
Research Site Orangeburg South Carolina 29118
Research Site Summerville South Carolina 29486
Research Site Memphis Tennessee 38119
Research Site Carrollton Texas 75007-1601
Research Site Dallas Texas 75231
Research Site League City Texas 77573
Research Site Mesquite Texas 75150
Research Site Plano Texas 75024
Research Site Olympia Washington 98502
Research Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02792699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2020 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02792699 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →